为了客观评估紫龙金片对非小细胞肺癌(NSCLC)的疗效，并基于网络药理学研究探索其针对NSCLC和COVID-19的潜在作用机制。在数据库中搜索截至2022年8月22日发表的紫龙金片用于NSCLC的随机对照试验(RCTs)。使用Cochrane标准指南评估包含试验的质量，并使用Rev Man 5.3进行荟萃分析。从TCMSP数据库、HERB数据库、GeneCards数据库和NCBI数据库获得与NSCLC和COVID-19交叉的基因靶点及药物，用于网络药理学研究。 荟萃分析包括14篇文章，涉及2,430名患者。荟萃分析表明，紫龙金片与常规化疗相结合在NSCLC治疗中比单独化疗显著更有效。网络药理学鉴定出29个药物-疾病交叉靶点。"成分-靶点-通路"图示组分-靶点-通路网络涵盖了119个节点和429条边，其中大多数靶点与炎症反应相关。 紫龙金片与常规化疗相结合的NSCLC疗效和生活质量明显优于单独化疗，减轻了各种不良反应。同时，紫龙金片可能通过调节炎症反应来缓解NSCLC和COVID-19。 版权所有©2023 Yang、Zhang、Gao、Hu、Yang和Xu。

To objectively evaluate the efficacy of the Zilongjin tablets in non-small cell lung cancer (NSCLC) and to explore its potential mechanism of action against NSCLC and COVID-19 based on network pharmacology.The database was searched for randomized controlled trials (RCTs) of the Zilongjin tablets for NSCLC published up to 22 August 2022. The quality of included trials was assessed using Cochrane standard guidelines, and a meta-analysis was performed using Rev Man 5.3. Gene targets for intersections of NSCLC and COVID-19 (the NC) and drugs were obtained from the TCMSP database, HERB database, GeneCards database, and the NCBI database for network pharmacology research.Meta-analysis included 14 articles with 2,430 patients. The meta-analysis showed that the Zilongjin tablets combined with conventional chemotherapy were significantly more effective than chemotherapy alone in the treatment of NSCLC. A total of 29 drug-disease intersecting targets were identified in the network pharmacology. The "ingredient-target-pathway" diagram component-target-pathway network contained 119 nodes and 429 edges, with the majority of targets associated with inflammatory responses.The efficacy and quality of life of the Zilongjin tablets combined conventional chemotherapy for NSCLC were significantly better than chemotherapy alone, alleviating various adverse effects. At the same time, the Zilongjin tablets may modulate the inflammatory response to alleviate NSCLC and COVID-19.Copyright © 2023 Yang, Zhang, Gao, Hu, Yang and Xu.